PAR PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?
PAR PHARM has one hundred and fifty-three approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.
Summary for PAR PHARM
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 98 |
| Ingredients: | 96 |
| NDAs: | 153 |
| Patent Litigation for PAR PHARM: | See patent lawsuits for PAR PHARM |
| PTAB Cases with PAR PHARM as petitioner: | See PTAB cases with PAR PHARM as petitioner |
Drugs and US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm Inc | COLCHICINE | colchicine | TABLET;ORAL | 203976-001 | Aug 12, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | GLIPIZIDE | glipizide | TABLET, EXTENDED RELEASE;ORAL | 076159-001 | Sep 20, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | LEUCOVORIN CALCIUM | leucovorin calcium | TABLET;ORAL | 071600-001 | Oct 14, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE | chlorthalidone; clonidine hydrochloride | TABLET;ORAL | 071178-001 | Dec 16, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | OXANDROLONE | oxandrolone | TABLET;ORAL | 077827-001 | Jun 22, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | LAMOTRIGINE | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 204158-003 | Oct 27, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for PAR PHARM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5378788 | ⤷ Try a Trial |
| Canada | 2605413 | ⤷ Try a Trial |
| China | 101163679 | ⤷ Try a Trial |
| Mexico | 2007013118 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Try a Trial |
| Australia | 2006240490 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PAR PHARM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1507558 | 2012/018 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
| 2563920 | CA 2019 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710 |
| 0663916 | CA 2004 00020 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS |
| 3351246 | LUC00138 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001-008 20120725 |
| 2101777 | 300813 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125 |
| 2269604 | C02269604/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS (40-O-(2-HYDROXYETHYL)-RAPAMYCIN); REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 59174 17.11.2009 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
